Issued 2026-08-13 at $43.41 · now $39.98 (2026-08-13, −7.9% since)
Based on its own history, a month from the 2026-08-13 close, KOD has typically landed between $29.38 and $72.45 — a range of −32.3% to +66.9% from the issuance price $43.41.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,951 overlapping 1 month windows · 2018-10-04 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($43.41) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where KOD has typically landed a month from the 2026-08-13 close of $43.41 — the range is history, not a prediction.
- now $39.98 (-7.9%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $44.28 (+2.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $35.37–$53.2
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $29.38–$72.45
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-07-21 | −67.5% | −67.5% | +0.0% |
| 2023-07-20 | −64.8% | −64.8% | +3.0% |
| 2023-07-19 | −64.2% | −64.2% | +0.8% |
| 3 best | |||
| 2019-11-01 | +233.6% | −3.6% | +233.6% |
| 2019-11-06 | +212.2% | +0.0% | +237.5% |
| 2019-11-05 | +204.0% | +0.0% | +246.2% |
1,951 overlapping windows · 2018-10-04 – 2026-08-13 · not cherry-picked
Pending catalysts
- February 2027 — Trial primary completion: Phase 3 primary completion: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE (source, as of 2026-08-14)
- April 2027 — Trial primary completion: Phase 3 primary completion: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.